Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study.

Journal of cardiovascular pharmacology - 1 Oct 2025

Trincado Ave Mauro, Brión María, Blanco-Verea Alejandro, Gil Almudena, Tilves Carlos, Seoane Blanco Ana, Moure González María, García-Rodeja Federico, de la Fuente Pablo, González-Juanatey José Ramón, Rodríguez Mañero Moisés

Abstract excerpt

A 25% flecainide dose reduction has been recommended for intermediate metabolizers (IMs); however, studies have yielded contradictory results, likely because of the lack of standardization in CYP2D6 pharmacogenetic classifications. We aimed to address this gap. This cohort study included atrial fibrillation patients prescribed flecainide between 2017 and 2021. CYP2D6 was analyzed, and patient phenotypes were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Arrhythmia Agents
Share to Atrial Fibrillation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Flecainide

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Recurrence

Share to Risk Assessment

Source

Identifiers

PMID: 40705539
DOI: 10.1097/FJC.0000000000001739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study.PMID 40705539Read ↗

Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.Semantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].Semantic proximity Read ↗

CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.Semantic proximity Read ↗

Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.Semantic proximity Read ↗

Understanding variation in metoprolol response: CYP2D6, drug interactions, and phenoconversion.Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic ExposureSemantic proximity Read ↗

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.Semantic proximity Read ↗

Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

Prescribed Doses of CYP2D6-Metabolized Drugs and Hemodynamic Responses in Relation to CYP2D6 Genotype Among Older Patients Exposed to Polypharmacy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.